Abstract 108P
Background
Multiple bilobar colorectal liver metastases (CLM) is a big challenge for surgeon oncologist due to high risk of postoperative morbidity and mortality. Two-stage hepatectomy (TSH) is a nowadays surgical standard. As alternative enhanced one-stage hepatectomy (e-OSH) with intraoperative ultrasound control to reduce the resection of the unaffected parenchyma could be performed.
Methods
665 patients with CLM who underwent liver resection at the Privolzhsky District Medical Center from 2010 to 2017 were retrospectively analyzed. Inclusion criteria were multiple CLM in one lobe with at least one lesion in the contralateral lobe. 76 patients (11,5%) were included in the study: 49 with TSH and 27 with e-OSH. Post-operative complications rate and overall survival in 2 groups were investigated and compared.
Results
Among 49 patients in first group (TSH) 23 reached to the second stage. Drop-out rate of TSH was 53%. Compared to the e-OSH patients who reached to the second stage had similar overall morbidity (TSH – 30.4% vs. e-OSH – 33.3% p = 0.827), liver-specific morbidity (TSH – 17.4% vs. e-OSH – 29.6%, p = 0.313) severe morbidity (TSH – 21.7% vs. e-OSH – 22.2% p = 0.968) and overall mortality (TSH – 8,7% vs. e-OSH – 14,8% p = 0.507). R0 resection rate was similar between groups. Completed TSH and e-OSH had similar overall survival rate (1-year 83% vs. 73% р = 0.313; 3-year 39% vs. 38% р = 0.880).
Conclusions
e-OSH may be considered as the surgical treatment of choice due to the absence of drop-out risk and a similar to TSH rate of morbidity, mortality, and overall survival. TSH is preferable to perform in cases where postoperative fatal liver insufficiency is highly likely.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
94P - Prognostic influence of mean platelet volume on stage III rectal cancer patients: A tertiary cancer center study
Presenter: Pavan Jonnada
Session: e-Poster Display Session
95P - Prognosis of Japanese patients with detailed RAS/BRAF mutant colorectal cancer
Presenter: Tatsuki Ikoma
Session: e-Poster Display Session
96P - Early-onset colorectal cancer prognosis, conflict resolution, review of literature and meta-analysis
Presenter: Ereny Poles
Session: e-Poster Display Session
97P - A population-based study to assess the associations of rural residence and low socioeconomic status (SES) with cardiovascular disease (CVD) in patients with colorectal cancer (CRC)
Presenter: Atul Batra
Session: e-Poster Display Session
98P - Operational challenges of an Asian Pacific (APAC) academic oncology clinical trial
Presenter: Daphne Day
Session: e-Poster Display Session
99P - Development of a qRT-PCR-based diagnostic test to identify colorectal cancer patients with recurrent R-Spondin gene fusions
Presenter: Veronica Diermayr
Session: e-Poster Display Session
100P - Individualized treatment of advanced digestive system tumour guided by PDTX mouse model: A multicenter trial
Presenter: yuan cheng
Session: e-Poster Display Session
101P - HIF1-α depletion overcomes resistance to oxaliplatin in colorectal cancer via ERK signalling pathway
Presenter: Se Jun Park
Session: e-Poster Display Session
102P - Colorectal cancer organoids culture exploits new neoadjuvant therapy resistance mechanisms and therapeutic targets
Presenter: Yun Deng
Session: e-Poster Display Session
103P - Comprehensive genomic landscape in younger and older Chinese patients with colorectal cancer
Presenter: Huina Wang
Session: e-Poster Display Session